Advertisement
New Zealand markets close in 2 hours 33 minutes
  • NZX 50

    11,756.40
    -108.49 (-0.91%)
     
  • NZD/USD

    0.6132
    -0.0012 (-0.20%)
     
  • NZD/EUR

    0.5726
    -0.0007 (-0.13%)
     
  • ALL ORDS

    7,956.00
    -18.80 (-0.24%)
     
  • ASX 200

    7,710.90
    -13.40 (-0.17%)
     
  • OIL

    78.27
    -0.18 (-0.23%)
     
  • GOLD

    2,340.10
    -9.00 (-0.38%)
     
  • NASDAQ

    19,659.80
    +82.90 (+0.42%)
     
  • FTSE

    8,146.86
    -16.81 (-0.21%)
     
  • Dow Jones

    38,589.16
    -57.94 (-0.15%)
     
  • DAX

    18,002.02
    -263.68 (-1.44%)
     
  • Hang Seng

    17,993.67
    +51.89 (+0.29%)
     
  • NIKKEI 225

    38,121.45
    -693.11 (-1.79%)
     
  • NZD/JPY

    96.5340
    -0.1180 (-0.12%)
     

Stereotaxis' (STXS) RMN System to Aid in Treating Arrhythmias

Stereotaxis STXS recently announced that the first robotic cardiac heart program in Southern Italy had been developed at Hospital Santa Maria della Pietà, Nola.

With the help of this cutting-edge technology, patients with heart rhythm abnormalities can now be effectively treated with robotic ablation treatments. Hospital Santa Maria della Pietà is the first hospital in Italy to use the latest generation of Genesis Robotic Magnetic Navigation (RMN) system.

Price Performance

For the past six months, STXS’s shares have gained 19.5% compared with the industry’s rise of 18%. The S&P 500 increased 15.9% in the same time frame.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

More on the RMN System

Genesis RMN system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Arrhythmias, or irregular heartbeats caused by the heart beating too rapidly, too slowly, or in an irregular pattern, affect millions of people globally. Arrhythmias have been shown to dramatically raise the risk of stroke, heart failure, and sudden cardiac arrest if left untreated.

ADVERTISEMENT

Genesis RMN technology is likely to help physicians target arrhythmias with unparalleled accuracy and lesser patient risk. This will enable physicians to perform cardiac ablation treatments with an unprecedented level of precision and control.

Industry Prospects

Per a report by Data Bridge Market Research, the global arrhythmia treatment market size was valued at $7.64 billion in 2022 and is expected to reach more than $11.06 billion by 2030 at a growth rate of 7.7%. Per a report by Global Market Insights, the global surgical navigation systems market size was valued at over $1 billion in 2022 and is expected to reach more than $1.8 billion by the end of 2023.

Given the market potential, the Genesis RMN system is likely to boost Stereotaxis’ business and generate additional revenues.

Notable Developments

In March 2024, Stereotaxis announced that it has entered into a definitive share purchase agreement under which Stereotaxis will acquire Access Point Technologies EP, a privately-held Minnesota-based developer of innovative electrophysiology catheters.

In February 2024, the company announced the first treatment of patients Genesis RMN system at Intermountain Medical Center, the flagship hospital of Intermountain Health, based in Salt Lake City.

Stereotaxis Inc. Price

Stereotaxis Inc. Price
Stereotaxis Inc. Price

Stereotaxis Inc. price | Stereotaxis Inc. Quote

Zacks Rank & Stocks to Consider

STXS carries a Zacks Rank #3 (Hold) at present.

Some better-ranked stocks in the broader medical space that have announced quarterly results are Align Technology, Inc. ALGN, Ecolab ECL and Boston Scientific Corporation BSX.

Align Technology, carrying a Zacks Rank of 2 (Buy), reported first-quarter 2024 adjusted earnings per share (EPS) of $2.14, beating the Zacks Consensus Estimate by 8.1%. Revenues of $997.4 million outpaced the consensus mark by 2.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology has a long-term estimated growth rate of 6.9%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 5.9%.

Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 1.7%.

Ecolab’s shares have rallied 33.8% against the industry’s 9.3% decline in the past year.

Boston Scientific reported first-quarter 2024 adjusted EPS of 56 cents, beating the Zacks Consensus Estimate by 9.8%. Revenues of $3.86 billion surpassed the Zacks Consensus Estimate by 4.9%. It currently carries a Zacks Rank #2.

Boston Scientific has a long-term estimated growth rate of 12.5%. BSX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 7.5%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Boston Scientific Corporation (BSX) : Free Stock Analysis Report

Ecolab Inc. (ECL) : Free Stock Analysis Report

Align Technology, Inc. (ALGN) : Free Stock Analysis Report

Stereotaxis Inc. (STXS) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research